CI

At a glance

ClinicalIndex Comparison Record
N/AUnknown· 40 target
Drug / intervention
Conditioning for CR group +3 moredrug
Likely dose
Conditioning for CR group 3gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02676856
NCT02676856N/AUnknown
CompareCT.gov

Hematopoietic Stem Cell Microtransplantation for Acute Myeloid Leukemia

Nanfang Hospital, Southern Medical University·interventional·Posted Feb 8, 2016·Updated Dec 8, 2017

In Brief

A clinical study evaluating hematopoietic stem cell microtransplantation-long-term, hematopoietic stem cell microtransplantation-short-term, and 2 other interventions for Acute Myeloid Leukemia. Targeting 40 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the efficacy of hematopoietic stem cell microtransplantation for in acute myeloid leukemia (AML)patients who can not receive hematopoietic stem cell transplantation (HSCT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesChina
CollaboratorsGuangzhou First People's Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Peking University People's Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Zhujiang Hospital

Timeline

N/AUnknownOverdue
20162017201820192020202120222023202420252026
First PostedFeb 8, 2016
Enrollment StartFeb 1, 2016
Primary CompletionFeb 1, 2018
Study CompletionAug 1, 2018
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 10.4 years ago

Interventions

hematopoietic stem cell microtransplantation-long-termprocedure

Stem cell infusion are administrated once three months for 3 times with the cell count of 3\*10\^8/kg/once.

hematopoietic stem cell microtransplantation-short-termprocedure

Stem cell infusion are administrated once every 45 days for 3 times with the cell count of 3\*10\^8/kg/once.

Conditioning for CR groupdrug

For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).

Conditioning for Non-CR groupdrug

For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).